These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11962119)

  • 1. Inter-provincial variation in government drug formularies.
    Grégoire JP; MacNeil P; Skilton K; Moisan J; Menon D; Jacobs P; McKenzie E; Ferguson B
    Can J Public Health; 2001; 92(4):307-12. PubMed ID: 11962119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dog's breakfast: prescription drug coverage varies widely across Canada.
    Anis AH; Guh D; Wang Xh
    Med Care; 2001 Apr; 39(4):315-26. PubMed ID: 11329519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breadth, Depth and Agreement among Provincial Formularies in Canada.
    Morgan S; Hanley G; Raymond C; Blais R
    Healthc Policy; 2009 May; 4(4):e162-84. PubMed ID: 20436800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to drugs for cancer: Does where you live matter?
    Menon D; Stafinski T; Stuart G
    Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does variation among provincial drug formulary antimicrobial listings in Canada influence prescribing rates?
    Glass-Kaastra SK; Finley R; Hutchinson J; Patrick DM; Weiss K; Conly J
    PLoS One; 2014; 9(9):e107515. PubMed ID: 25203557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.
    Marshall DA; Willison DJ; Grootendorst P; LeLorier J; Maclure M; Kulin NA; Sheehy OE; Warren L; Sykora K; Rahme E
    Health Policy; 2007 Nov; 84(1):1-13. PubMed ID: 17570558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable.
    Levy AR; Gagnon YM
    Healthc Pap; 2002; 3(1):32-7; discussion 87-94. PubMed ID: 12811108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.
    Demers V; Melo M; Jackevicius C; Cox J; Kalavrouziotis D; Rinfret S; Humphries KH; Johansen H; Tu JV; Pilote L
    CMAJ; 2008 Feb; 178(4):405-9. PubMed ID: 18268266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving Patient Access to New Drugs in South Korea: Evaluation of the National Drug Formulary System.
    Yoo SL; Kim DJ; Lee SM; Kang WG; Kim SY; Lee JH; Suh DC
    Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30669602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who's the fairest of them all? Which provincial pharmacare model would best protect Canadians against catastrophic drug costs?
    Coombes ME; Morgan SG; Barer ML; Pagliccia N
    Healthc Q; 2004; 7(4):suppl 13-9. PubMed ID: 15540402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceuticals issue brief: managed care drug formularies: year end report-2003.
    MacEachern L
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-8. PubMed ID: 14969259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada.
    Knowles SR; Lee K; Paterson JM; Shah BR; Mamdani MM; Juurlink DN; Gomes T
    Can J Diabetes; 2017 Apr; 41(2):138-142. PubMed ID: 27989494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Provincial disparities of growth hormone coverage for young adult survivors of paediatric brain tumours across Canada.
    Hasan H; Howard F; Morgan SG; Metzger DL; Lo AC; Goddard K; Gill S; Johnson M
    Healthc Policy; 2014 Feb; 9(3):80-96. PubMed ID: 24726076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whither seniors' pharmacare: lessons from (and for) Canada.
    Morgan SG; Barer ML; Agnew JD
    Health Aff (Millwood); 2003; 22(3):49-59. PubMed ID: 12757272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of anti-infective drug use in elderly persons in Manitoba, Nova Scotia, and Saskatchewan, Canada: relationship to drug insurance reimbursement policies.
    Sketris IS; Metge C; Shevchuk Y; Comeau DG; Kephart GC; Blackburn J; MacCara M; Laturnas A
    Am J Geriatr Pharmacother; 2004 Mar; 2(1):24-35. PubMed ID: 15555476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Need for an improved submission process for listing drugs for reimbursement in Canadian provinces.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Clin Pharmacol; 2003; 10(4):207-10. PubMed ID: 14712327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provinces create centralized system for assessing new drugs.
    Hillson G
    Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):31. PubMed ID: 14719493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.